Does Orforglipron Cause Thyroid Cancer? What the FDA Label Says

No, it isn’t established that orforglipron (Foundayo) causes thyroid cancer in people. But its FDA label does carry a boxed warning — the strongest warning the FDA applies — about thyroid C-cell tumors, because that’s a precaution required across the entire GLP-1 receptor agonist drug class. Here’s exactly what the label says, why the warning exists even though orforglipron didn’t cause tumors in its own animal studies, and who should avoid the drug entirely.

What orforglipron’s boxed warning actually says

Per the FDA-approved FOUNDAYO label, medicines that activate the GLP-1 receptor have caused thyroid C-cell tumors (adenomas and carcinomas) in rodent studies, at exposures relevant to human dosing. The label states this appears to be a GLP-1 receptor-dependent effect in rodents, and that whether it applies to humans has not been determined. That’s the core of the warning: a rodent finding, applied as a precaution across the drug class, with unresolved human relevance.

This isn’t unique to orforglipron. It’s the same class-wide boxed warning language that appears on the labels of other GLP-1 receptor agonists, including semaglutide (Ozempic, Rybelsus) and tirzepatide (Mounjaro, Zepbound), per MedlinePlus drug information on those medications.

The nuance specific to orforglipron

Here’s where orforglipron differs mechanically from some of the injectable and peptide GLP-1 drugs: it’s a small molecule, not a peptide, and per its FDA label it did not produce thyroid C-cell tumors in the rodent carcinogenicity studies conducted for its own approval. Orforglipron also isn’t pharmacologically active at the rodent version of the GLP-1 receptor the same way some peptide GLP-1 drugs are — which is part of why its own animal studies didn’t show the tumor signal that drove the original warning for the class.

Despite that, the FDA still required the boxed warning on orforglipron’s label. Two things justify it: the human relevance of the rodent finding remains undetermined for the class as a whole, and cases of medullary thyroid carcinoma (MTC) have been reported in people taking other GLP-1 receptor agonist medicines. In other words, orforglipron’s own animal data didn’t show the tumor finding, but it still carries the same precautionary label as the rest of its drug class.

Who should not take orforglipron

Per the FDA label, orforglipron is contraindicated — meaning it should not be used — in people with:

• A personal or family history of medullary thyroid carcinoma (MTC), a specific type of thyroid cancer.
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), an inherited condition that raises the risk of MTC and other endocrine tumors.

If either applies to you or a close family member, tell your prescriber before starting orforglipron — this isn’t a “discuss the tradeoffs” situation, it’s a reason the drug shouldn’t be prescribed.

Symptoms to report to your prescriber

Per the FDA label, patients taking orforglipron should watch for and promptly report:

• A lump or swelling in the neck
• Persistent hoarseness
• Trouble swallowing (dysphagia)
• Trouble breathing (dyspnea)

These are the symptoms the label specifically associates with thyroid tumors. None of them are exclusive to thyroid cancer, and having one doesn’t mean you have it — but the label calls them out because they’re the ones worth flagging quickly rather than waiting to mention at a routine visit.

How orforglipron’s thyroid warning compares across GLP-1s

Here’s how the boxed warning and its contraindications compare across orforglipron and the other major GLP-1 medications, based on their respective labels and MedlinePlus drug information:

	Orforglipron (Foundayo)	Semaglutide (Ozempic, Rybelsus)	Tirzepatide (Mounjaro, Zepbound)
Molecule type	Small molecule	Peptide	Peptide
Boxed warning for thyroid C-cell tumors	Yes	Yes	Yes
Tumors seen in the drug’s own rodent studies	No, per FDA label	Class-wide rodent finding applies	Class-wide rodent finding applies
Contraindicated in personal/family history of MTC or MEN 2	Yes	Yes	Yes
Human relevance of rodent finding established	Not determined, per label	Not determined	Not determined

The takeaway from this table isn’t that one drug is “safer” on this specific point — the contraindication and the patient-counseling requirements are the same across all three. The difference is limited to what showed up (or didn’t) in each drug’s own animal testing.

What this doesn’t mean

This warning does not mean orforglipron is known to cause thyroid cancer in people who take it, and it isn’t a reason for someone without MTC or MEN 2 history to avoid the drug on this basis alone. Boxed warnings communicate a serious, labeled risk that prescribers and patients should be aware of — they don’t necessarily mean the risk has been confirmed to occur in humans at the studied doses. For orforglipron specifically, the label is explicit that this is a precautionary class-wide warning layered onto a drug whose own rodent studies didn’t produce the tumor finding.

If you’re weighing this alongside other safety questions, our orforglipron side effects guide covers the much more common gastrointestinal side effects, the Foundayo dosing guide walks through the full titration schedule, and Orforglipron vs Ozempic covers how orforglipron compares to injectable and oral semaglutide more broadly.

Bottom line

Orforglipron carries the same FDA boxed warning for thyroid C-cell tumors as other GLP-1 receptor agonists, and it’s contraindicated for anyone with a personal or family history of MTC or MEN 2. Its own rodent studies didn’t produce thyroid tumors, but the FDA still requires the class-wide precaution because the human relevance of the underlying rodent finding hasn’t been determined. If you have thyroid cancer risk factors, tell your prescriber before starting — and report any neck lump, persistent hoarseness, or trouble swallowing or breathing while on treatment, per the label’s guidance. This is educational information, not medical advice; your prescriber is the right person to evaluate your personal risk.